A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 PEG-SN38) Administered Weekly for 3 Weeks in 4-Week Cycles in Patients With Advanced Solid Tumors or Ymphoma (EZN-2208-02)
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the MTD of i.v. EZN-2208 administered weekly for 3 weeks in a 4-week cycle and recommended Phase 2 dose of i.v. EZN-2208
Amita Patnaik, M.D.
Principal Investigator
South Texas Accelerated Research Therapeutics
United States: Food and Drug Administration
EZN-2208-02
NCT00520390
May 2007
Name | Location |
---|---|
South Texas Accelerated Research Therapeutics | San Antonio, Texas 78229 |